Thomas Jefferson University

Jefferson Digital Commons
Department of Pediatrics Faculty Papers

Department of Pediatrics

10-14-2016

Identification of early gene expression changes in primary
cultured neurons treated with topoisomerase I poisons.
Sharyn L. Rossi
Nemours Alfred I. duPont Hospital for Children

Casey J. Lumpkin
Nemours Alfred I. duPont Hospital for Children; University of Delaware

Ashlee W. Harris
Nemours Alfred I. duPont Hospital for Children

Jennifer Holbrook
Nemours Alfred I. duPont Hospital for Children

Cinsley
Gentillon
Follow this
and additional works at: https://jdc.jefferson.edu/pedsfp

Nemours Alfred I. duPont Hospital for Children; University of Delaware
Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Rossi, Sharyn L.; Lumpkin, Casey J.; Harris, Ashlee W.; Holbrook, Jennifer; Gentillon, Cinsley;
McCahan, Suzanne M.; Wang, Wenlan; and Butchbach, Matthew E.R., "Identification of early
gene expression changes in primary cultured neurons treated with topoisomerase I poisons."
(2016). Department of Pediatrics Faculty Papers. Paper 76.
https://jdc.jefferson.edu/pedsfp/76
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Pediatrics Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Sharyn L. Rossi, Casey J. Lumpkin, Ashlee W. Harris, Jennifer Holbrook, Cinsley Gentillon, Suzanne M.
McCahan, Wenlan Wang, and Matthew E.R. Butchbach

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/pedsfp/76

HHS Public Access
Author manuscript
Author Manuscript

Biochem Biophys Res Commun. Author manuscript; available in PMC 2017 October 14.
Published in final edited form as:

Biochem Biophys Res Commun. 2016 October 14; 479(2): 319–324. doi:10.1016/j.bbrc.2016.09.068.

Identification of early gene expression changes in primary
cultured neurons treated with topoisomerase I poisons
Sharyn L. Rossia,*, Casey J. Lumpkina,e,*, Ashlee W. Harrisa,*, Jennifer Holbrookc, Cinsley
Gentillona,e, Suzanne M. McCahanb,d,f, Wenlan Wanga,b,**, and Matthew E. R.
Butchbacha,b,e,f
aCenter

Author Manuscript

for Applied Clinical Genomics, Nemours Biomedical Research, Nemours Alfred I. duPont
Hospital for Children, Wilmington, Delaware, United States of America

bCenter

for Pediatric Research, Nemours Biomedical Research, Nemours Alfred I. duPont
Hospital for Children, Wilmington, Delaware, United States of America
cBiomolecular

Core Laboratory, Nemours Biomedical Research, Nemours Alfred I. duPont
Hospital for Children, Wilmington, Delaware, United States of America
dBioinformatics

Core Facility, Nemours Biomedical Research, Nemours Alfred I. duPont Hospital
for Children, Wilmington, Delaware, United States of America
eDepartment

of Biological Sciences, University of Delaware, Newark, Delaware, United States of

America
fDepartment

Author Manuscript

of Pediatrics, Thomas Jefferson University, Philadelphia, Pennsylvania, United
States of America

Abstract
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Topoisomerase 1 (TOP1) poisons like camptothecin (CPT) are currently used in cancer
chemotherapy but these compounds can have damaging, off-target effects on neurons leading to
cognitive, sensory and motor deficits. To understand the molecular basis for the enhanced
sensitivity of neurons to CPT, we examined the effects of compounds that inhibit TOP1—CPT,
actinomycin D (ActD) and β-lapachone (β-Lap)—on primary cultured rat motor (MN) and
cortical (CN) neurons as well as fibroblasts. Neuronal cells expressed higher levels of Top1
mRNA than fibroblasts but transcript levels are reduced in all cell types after treatment with CPT.
Microarray analysis was performed to identify differentially regulated transcripts in MNs in
response to a brief exposure to CPT. Pathway analysis of the differentially expressed transcripts
revealed activation of ERK and JNK signaling cascades in CPT-treated MNs. Immediate-early
genes like Fos, Egr-1 and Gadd45b were upregulated in CPT-treated MNs. Fos mRNA levels were
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elevated in all cell types treated with CPT; Egr-1, Gadd45b and Dyrk3 transcript levels, however,
increased in CPT-treated MNs and CNs but decreased in CPT-treated fibroblasts. These transcripts
may represent new targets for the development of therapeutic agents that mitigate the off-target
effects of chemotherapy on the nervous system.

Keywords
motor neuron; cortical neuron; camptothecin; actinomycin D; β-lapachone; DNA damage
response; immediate early gene; microarray; Dyrk3
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Topoisomerase I (TOP1) relaxes DNA supercoiling so that replication and gene transcription
can proceed. TOP1 introduces single-strand DNA breaks, or nicks, in the supercoiled DNA
by covalently binding to the DNA and forming a TOP1 cleavage complex (TOP1cc) [1].
Once the DNA is sufficiently unwound, the TOP1cc facilitates the religation of the nick and
TOP1 is released from the DNA. TOP1ccs are normally very transient structures;
camptothecin (CPT) and its derivatives act as interfacial inhibitors of TOP1 by reversibly
stabilizing the complex. This stabilization prevents the religation of the double-stranded
DNA [1] resulting in double-strand DNA breaks. As such, CPT-based compounds are
sometimes referred to as TOP1 poisons as opposed to inhibitors [2]. Actinomycin D (ActD),
in addition to its action as a transcription inhibitor [3], also stabilizes the TOP1cc and,
therefore, acts as a TOP1 poison [4]. Alternatively, β-lapachone (β-Lap) is a direct inhibitor
of TOP1 and does not interact with the TOP1cc [5].

Author Manuscript

Anti-cancer drugs like CPT and its derivatives can cause DNA damage and oxidative stress
in non-target tissues like neurons [1;2]. The non-specific action of chemotherapy drugs on
the central nervous system may contribute to chemotherapy-induced cognitive impairment, a
phenomenon formerly known as “chemobrain” [6]. Dysarthria, which is an impairment of
the motor component of speech, has been observed in cancer patients treated with the CPT
prodrug irinotecan [7;8].

Author Manuscript

Neurons are exceptionally susceptible to DNA damaging agents like CPT because they
maintain high levels of RNA synthesis and are more sensitive to oxidative stress [9]. We
hypothesize that neurons differentially regulate the expression of genes that confer this
increased susceptibility. In this study, we identified, by microarray, early transcripts
differentially regulated in primary cultured rat neuronal (motor (MN) and cortical (CN)
neurons) and non-neuronal (fibroblasts) cells after a brief exposure to the TOP1 inhibiting
agents CPT, ActD and β-Lap.

MATERIALS AND METHODS
Ethics Statement
All animal experiments were conducted in accordance with the protocols described in the
National Institutes of Health Guide for the Care and Use of Animals and were approved by
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the Nemours Biomedical Research Institutional Laboratory Animal Care and Use
Committee.
Embryonic Rat Primary Culture
Primary cultures of rat MNs, CNs and fibroblasts were obtained from embryonic day 15
(e15) Sprague-Dawley rat pups. Timed-pregnant dams (Charles River; Wilmington, MA)
were deeply anesthetized using CO2 and individual embryos were placed on ice in Hank’s
balanced salt solution (HBSS; Life Technologies, Grand Island, NY) after the uteri were
remove. CNs and MNs were plated at a density of 5.0 × 104 cells/cm2 on coverslips coated
with 100 μg/mL poly-DL-ornithine (Sigma) and 2 μg/mL laminin (Millipore, Billerica, MA)
for immunofluorescence or at a density of 2.5 × 106 cells/cm2 on 10-cm dishes coated with
poly-DL-ornithine and laminin for RNA extraction. Fibroblasts were plated at the same
density but on gelatin-coated coverslips or 10-cm dishes.
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For primary CNs and MNs, superficial segments of the forebrain or thoracolumbar spinal
cords were dissected from embryos, rinsed in HBSS and incubated in 0.05% trypsin/EDTA
(Life Technologies, Grand Island, NY) for 15 minutes at 37°C. After trypsinization, the cells
were triturated in Neuron Medium (Neurobasal medium supplemented with 1% B27, 2%
horse serum, 500 μM L-glutamine, 1% penicillin/streptomycin (pen/strept), (all from Life
Technologies, Grand Island, NY), 25 mM β-mercaptoethanol (Sigma-Aldrich, St. Louis,
MO) and 1 ng/mL brain-derived neurotrophic factor (BDNF; R&D Systems, Minneapolis,
MN)). MNs were separated from other spinal cord dissociated cells using Opti-Prep (SigmaAldrich; final concentration = 3%; 500xg for 15 minutes) and then centrifuged (300xg for 10
minutes) through a 4% bovine serum albumin (BSA; Sigma, St. Louis, MO) cushion. Both
MNs and CNs were maintained in Neuron Medium.
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Primary fibroblasts were harvested from the white tissues of the embryo by trypsinization.
The pellets were resuspended in high glucose DMEM supplemented with 10% FBS, 2mM
L-glutamine and 1% pen/strept. They were maintained in T-150 flasks for 2 passages prior to
experiments.
These culturing conditions yielded high purities of the targeted cell types from embryonic
rat tissues as shown using cell type-specific markers (β3-tubulin, neurofilaments and Fox3
for neurons, HB9 for MNs and fibronectin for fibroblasts; data not shown). In the primary
CNs and MN cultures, there were very few (less than 5%) GFAP+ glial cells present.
Drug Response Assays
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Rat embryonic primary MNs, CNs and fibroblasts were treated with either DMSO (drug
vehicle) or different concentrations of the following TOP1 inhibitors (n=3/dose/drug):
camptothecin (CPT; Tocris Biosciences, Bristol, UK; 10 nM – 100 μM), β-lapachone (βLap, Sigma-Aldrich; 10 nM – 10 μM), and actinomycin D (ActD, Sigma-Aldrich; 10 nM –
10 μM). Primary cultures were treated for 24 hours starting at either 2 days in vitro (DIV2)
or 5 days in vitro (DIV5).
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Cells were fixed with 4% paraformaldehyde in PBS, pH 7.4 for 15 minutes at room
temperature. The cultures were then rinsed in PBS, permeabilized with 0.1% Triton-X100
(Sigma, St. Louis, MO) in PBS and then blocked with 5% normal donkey serum (Jackson
Immunoresearch, West Grove, PA) in PBS for one hour at room temperature. Coverslips
were then incubated with primary antibodies (see Supplementary Table 1) overnight at 4°C,
rinsed and incubated with combinations of AlexaFluor 488- and AlexaFluor 594-conjugated
anti-rabbit and anti-mouse IgGs (Life Technologies; 1:500) for 60 minutes at room
temperature. The cells were counterstained with Hoechst 33258 (1 μg/mL; Life
Technologies) for 10 minutes at room temperature and mounted onto glass microscope
slides with fluorescent mounting medium (DAKO, Carpenteria, CA). Cells were imaged
using a DMRXA2 epifluorescence microscope (Leica Microsystems) with an ORCA-ER
cooled CCD camera (Hamamatsu, Hamamatsu City, Japan) and OpenLab 5 software
(Improvision Ltd, Lexington, MA).
Images from 5 representative fields (392 μm × 512 μm) were collected from each coverslip
using a 20× objective. After the first field was selected, non-overlapping images were
captured above, below, to the left and to the right of the first field. The non-pyknotic cells
were counted using ImageJ (National Institutes of Health, Bethesda, MD). The cell counts
were averaged for each coverslip. Relative viability was defined as the percentage of nonpyknotic cells in response to TOP1 inhibitor treatment relative to DMSO-treated cells.
RNA Isolation
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Primary cultures at DIV2 were treated with 1 μM CPT, 4 μM β-Lap, 1 μM ActD or DMSO
for 2 hours. Total RNA was isolated from rat embryonic primary MNs, CNs and fibroblasts
using the RNeasy Mini kit (QIAGEN, Valencia, CA) according to the manufacturer’s
directions. RNA integrity was assessed using the 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA).
Microarray Analysis
Targets were prepared from 200 ng RNA using the Applause WT-Amp Plus ST System with
the Encore Biotin Module (NuGEN, Inc., San Carlos, CA) following the manufacturer’s
protocol. Samples were hybridized to GeneChip Rat Gene 1.0ST Arrays (Affymetrix). These
arrays were washed and stained in a GeneChip Fluidic Station 450 (Affymetrix) and then
scanned with the GeneChip scanner 3000 7G (Affymetrix) following the manufacturer’s
protocols. The raw data were deposited into the NCBI Gene Expression Omnibus (GEO)
under the accession number GSE67146.
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Microarray Data Analysis
Expression values were calculated and LIMMA (linear models for microarray analysis) was
performed as described previously [10]. The rank product non-parametric method RankProd
was also used [11]. A false discovery rate (FDR) and an estimated percentage false positive
(PFP) value less than 0.05 were considered significant. Identification of biological pathways
and upstream regulators in rat MNs affected by CPT was completed using Ingenuity

Biochem Biophys Res Commun. Author manuscript; available in PMC 2017 October 14.

Rossi et al.

Page 5

Author Manuscript

Pathway Analysis (IPA version 21901358; QIAGEN Redwood City, Inc., Redwood City,
CA) as described previously [12].
Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR)
qRT-PCR was performed on drug treated samples as described previously [12] except that
glyceraldehyde 3-phosphate dehydrogenase (Gapd), ribosomal protein L13a (Rpl13a) and βactin (Actb) were used as reference transcripts (see Supplementary Table 2 for primer
sequences).
Statistical Analysis
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All quantitative data are expressed as means ± standard errors. Cell viability data were
analyzed by ANOVA with a Bonferroni post hoc test. The qRT-PCR data were analyzed with
T-tests. Statistical significance was set at p ≤ 0.05. Statistical analyses of the quantitative
data were completed using SPSS v.22.

RESULTS
Differential Responses of Various Cell Types to TOP1 Poisons and Inhibitors
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We examined the effect of 3 TOP1 inhibitors—CPT, β-Lap and ActD—on the viability of
CNs and MNs as well as fibroblasts. Immature (DIV2) and more mature (DIV5) cells were
treated with TOP1 inhibitors for 24 hours. Cell viabilities were expressed relative to DMSOtreated cells. At DIV2, both CNs and MNs were more sensitive to CPT compared to
fibroblasts (Figures 1A and 1D). With time in culture, fibroblasts became sensitive to the
toxic effects of CPT. In contrast, the sensitivities of CNs and MNs to CPT did not markedly
change over time. All 3 cell types were equally susceptible to β-Lap-induced toxicity at both
time points but they were more resistant to β-Lap toxicity at DIV5 than DIV2 (Figures 1B
and 1E). At DIV2, ActD yielded similar toxic effects in all cell types examined (Figure 1C);
however, MNs at DIV5 were more sensitive to ActD toxicity than either CNs or fibroblasts
(Figure 1F). Taken together, neurons were more sensitive to the toxic effects of TOP1
poisons than fibroblasts.
Differential Expression of Top1 mRNAs and CPT Sensitivity
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MNs and CNs may be more sensitive to TOP1 poison-induced toxicity because these cells
may contain more TOP1 than other cell types. We compared basal Top1 mRNA levels
between MNs, CNs and fibroblasts using qPCR. Top1 transcript levels were 3.8- and 4.5fold higher in CNs and MNs, respectively, than in fibroblasts (Figure 2A). Transient
treatment with 1 μM CPT for 2 hours resulted in reduced Top1 mRNA levels in all 3 cell
types; the magnitude of change was higher in CNs and MNs than in fibroblasts (Figure 2B).
Additionally, treatment of MNs with β-Lap and ActD for 2 hours reduced Top1 mRNA
levels (Figure 2C).
Identification of Differentially Expressed RNAs in Response to CPT Treatment in MNs
To identify RNA transcripts whose levels are affected by CPT, DIV2 rat primary MNs were
treated with either 1 μM CPT or DMSO (n = 3/group) for 2 hours. This concentration was

Biochem Biophys Res Commun. Author manuscript; available in PMC 2017 October 14.

Rossi et al.

Page 6

Author Manuscript

selected as it was the LC50 in rat primary MNs (1.1 ± 0.2 μM). Since there was minimal
DNA damage and no cell death in treated MNs at this time point, cell death pathways should
not be over-represented in the analysis of differentially expressed transcripts at this early
time point. Differentially expressed transcripts were identified from the resultant microarray
data using LIMMA and RankProd. 926 gene IDs (664 downregulated and 262 upregulated)
were identified by both LIMMA and RankProd as being significantly different between
CPT- and vehicle-treated MNs. Ingenuity Pathway Analysis (IPA) mapped 594 identified
transcripts (142 upregulated and 452 downregulated; Supplementary Table 3) whose levels
were altered by CPT, after manual removal of redundant probe set IDs.
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To assess the biological relevance of the differentially expressed transcripts in CPT-treated
MNs, we used the IPA Ingenuity Knowledge Base repository of literature-based biological
data and its Upstream Regulator Analysis (URA) feature to identify overrepresented
signaling pathways [13]. Given that there was a large number of canonical pathways
overrepresented (Supplementary Table 4), analysis of these canonical pathways along with
URA (Supplementary Table 5) suggest that MAP kinase and JNK signal transduction
pathways are activated in MNs in response to CPT.
Validation of Differentially Expressed Transcripts Identified by Microarray Analysis
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We used qRT-PCR to validate the changes in the mRNA levels of transcripts in MNs
identified by microarray analysis in response to CPT using biological replicates. 4
transcripts—FBJ murine osteosarcinoma viral oncogene homolog (Fos), early growth
response 1 (Egr1), dual-specificity tyrosine-phosphorylation regulated kinase 3 (Dyrk3) and
growth arrest and DNA-damage-inducible β (Gadd45b)—were selected because they
exhibited strong induction in response to CPT treatment and, in some cases, have been
previously identified as being upregulated in response to CPT [14–16]. Exposure to CPT for
2 hours increased the mRNA levels of Fos, Egr2, Dyrk3 and Gadd45b in MNs (Figure 3A).
Are the changes in these transcripts the specific result of CPT treatment or a generalized
consequence of TOP1 inhibition? The changes in the levels of Fos, Egr2, Dyrk3 and
Gadd45b mRNAs were measured in MNs treated with β-Lap (4 μM) or ActD (1 μM) for 2
hours. These changes were compared to those elicited by 1 μM CPT treatment. The inhibitor
concentrations used here were close to the LC50s for each compound in MNs. The induction
of all four mRNAs in response to CPT was smaller than the responses of MNs to ActD
(Figure 3B). β-Lap increased Egr2, Dyrk3 and Gadd45b mRNA levels in MNs more
strongly than did CPT.
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We next determined if the effects of CPT on target gene expression were unique to MNs.
The levels of Fos, Egr2, Dyrk3 and Gadd45b mRNAs were measured in CNs and fibroblasts
treated with 1 μM CPT for 2 hours. Fos mRNA levels were increased in all 3 cell types
(Figure 3C). Interestingly, the levels of Egr2, Dyrk3 and Gadd45b mRNAs were elevated in
CPT-treated CNs—as in treated MNs—but were reduced in CPT-treated fibroblasts (Figures
3D–F).
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DISCUSSION
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We showed in this study that CNs and MNs were more susceptible to the toxic effects of
CPT than fibroblasts. This is consistent with other findings that exposure of CNs, MNs and
cerebellar granule cell (CGC) neurons to CPT leads to apoptotic death [17–20]. Why are
MNs and CNs more susceptible than fibroblasts to the toxic effects of TOP1 poisons? The
abundance of TOP1 in these cells may explain the differential sensitivity to CPT and ActD.
Short hairpin RNA (shRNA)-mediated suppression of TOP1 expression in lymphoma cells
confers resistance to CPT toxicity [21]. TOP1 is expressed in the central nervous system,
especially in inhibitory neurons [22]. We show here that Top1 mRNA levels were higher in
cultured CNs and MNs, which were more sensitive to CPT and ActD toxicity, than in
fibroblasts. Treatment of MNs, CNs and fibroblasts with CPT resulted in a rapid (2 hours)
decline in Top1 mRNA levels. Those cell types with higher basal Top1 levels showed a
sharper decline in Top1 expression in response to CPT suggesting that the increased
susceptibility of CNs and MNs to CPT may be independent of TOP1 expression.
CPT reduces the transcription of genes into mRNAs by RNA polymerase II [23]. mRNAs
transcribed from long genes are downregulated in response to CPT in cancer cell lines,
fibroblasts and in neurons while those from short genes show increased levels [24–26].
Some of these long transcripts suppressed by CPT are linked to autism [25]. In CNs, many
of these transcripts suppressed by CPT encode synaptic proteins and, as a result, excitatory
and inhibitory neurotransmission is reversibility blocked by CPT [27]. These observations
along with our study collectively highlight the importance of TOP1 in transcriptional
regulation in neurons and could explain why they are more sensitive to TOP1 poisons like
CPT and ActD.
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To delineate the early mechanisms of the neuronal response to CPT, we identified
differentially expressed transcripts in CPT-treated MNs using microarrays. DNA damage
response and cell death pathways were not overrepresented in the differentially expressed
transcripts of MNs treated with CPT for 2 hours. Many of these differentially expressed
transcripts are classified as immediate early genes (IEGs) in that their expression is rapidly
regulated in response to stimulus or injury [28]. CPT rapidly induces the transcription of
IEGs like Fos, Jun and Egr1 in non-neuronal cells [14–16] as well as in neurons (this study).
The IEGs Fos and Jun were upregulated in response to DNA damage induced by CPT and
likely mediated their downstream effects through activation of ERK and JNK MAP kinases.
ERK and JNK activities are increased in CNs shortly after treatment with CPT [18;29].
URA of upregulated transcripts revealed early activation of MAPK and JNK pathways in
MNs in response to CPT.
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DYRK3 is a member of a family of dual-specificity tyrosine-related protein kinases that
autophosphorylate on tyrosine residues as well as phosphorylate serine and threonine amino
acids on other proteins [30]. In this study, we have shown that Dyrk3 mRNA levels were
upregulated in neurons in response to CPT treatment. DYRKs are implicated in many
intracellular processes including cell survival/death, differentiation and gene expression
[31]. DYRKs differentially regulate the activity of certain substrates like p53, a key mediator
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in the DNA damage response [32–34]. Future studies will delineate the role of DYRK3 in
the response of neurons to TOP1 poisons as well as other forms of injury.
In summary, we have identified transcripts like Egr2, Gadd45b and Dyrk3 which are
increased in neuronal cells, but not in non-neuronal fibroblasts, in response to transient CPT
treatment. These early response transcripts could help explain the enhanced sensitivity of
neurons to TOP1 poisons. These differentially upregulated transcripts could become targets
for the development of therapeutic strategies which minimize neuronal damage in response
to chemotherapy.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
•

Cultured neurons are more sensitive than fibroblasts to camptothecin
and actinomycin D toxicity

•

Topoisomerase I mRNA levels are higher in neurons than in fibroblasts

•

Camptothecin increases Egr-1, Gadd45b and Dyrk3 in neurons but not
fibroblasts
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Figure 1. Effects of TOP1 inhibitors on the viability of rat embryonic primary MNs, CNs and
fibroblasts

Primary cultures of rat MNs (closed triangles), CNs (open circles) and fibroblasts (closed
circles) at DIV2 (A–C) or DIV5 (D–F) were treated with different concentrations of CPT
(A, D), β-Lap (B, E) or ActD (C, F) for 24 hours (n = 3/treatment). After treatment, the
number of viable cells was counted for each condition. Cell viabilities were expressed
relative to DMSO-treated cells. The asterisk (*) denotes a statistically significant difference
(p ≤ 0.05) relative to DMSO-treated cells.
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Figure 2. Effects of TOP1 inhibitors on Top1 mRNA expression in rat embryonic primary
cultures

Author Manuscript

The levels of Top1 mRNA were measured using qRT-PCR in cells treated with drugs (n = 3/
treatment). (A) The relative amounts of Top1 mRNA in rat embryonic primary CN and MN
cultures relative to Top1 mRNA levels in rat fibroblasts. The magnitude of change is
expressed as log2(fold change). The asterisk (*) denotes a statistically significant difference
(p ≤ 0.05) relative to the magnitude of change in fibroblasts. (B) The magnitude of change in
Top1 mRNA levels in CPT-treated MNs, CNs or fibroblasts relative to DMSO-treated cells.
The asterisk (*) denotes a statistically significant difference (p ≤ 0.05) relative to DMSOtreated cells. (C) The magnitude of change in Top1 mRNA levels in rat MNs treated with
CPT (grey bar), β-Lap (dark grey bar) or ActD (light grey bar) relative to DMSO-treated
(black bar) MNs. The asterisk (*) denotes a statistically significant difference (p ≤ 0.05)
relative to DMSO-treated MNs.
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Figure 3. Expression of differentiated expressed transcripts identified by microarray in TOP1
poison-treated cells
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The levels of Fos, Egr2, Dyrk3 and Gadd45b transcripts were measured using qRT-PCR in
cells treated with drugs (n = 3/treatment). (A) The magnitude of change (log2(fold change))
of target transcripts in CPT-treated rat MNs as determined by microarray (black bars) or
qRT-PCR (grey bars). (B) The magnitude of change of target transcripts in rat MNs treated
with CPT (black bars), β-Lap (light grey bars) or ActD (dark grey bars) relative to DMSOtreated MNs. The magnitudes of change of Fos (C), Egr2 (D), Dyrk3 (E) and Gadd45b (F)
in CPT-treated MNs, CNs or fibroblasts relative to DMSO-treated cells. The asterisk (*)
denotes a statistically significant difference (p ≤ 0.05) relative to DMSO-treated cells.
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